

Memorandum

PREPARED FOR: Senate Committee on Rules and
Executive Appointments

DATE: September 10, 2024

BY: Leslie Porter, Legislative Analyst

RE: Legislative Review of Executive Appointments



LPRO
LEGISLATIVE POLICY
AND RESEARCH OFFICE

PRESCRIPTION DRUG AFFORDABILITY BOARD

The Governor has appointed the following individuals to the Prescription Drug Affordability Board, subject to Senate confirmation:¹

New Appointment

Lauri Hoagland of Ashland

Reappointments

Amy Burns of Grants Pass

John Murray of Heppner

Terms

Hoagland: October 1, 2024 – December 31, 2026

Reappointees: January 1, 2025 – December 31, 2028

Statutory Authority

[ORS 646A.693 \(2023\)](#).

Statement of Economic Interest²

Not required.

Composition³

The board consists of eight Oregon residents with expertise in health care economics and clinical medicine, serving staggered terms:

- two members serving a term ending December 31, 2024 (**BURNS, MURRAY**);
- three members serving a term ending December 31, 2025 (HARTUNG, KENNEDY, LAMAN); and
- three members, including the chair, serving a term ending December 31, 2026 (BAILEY, **HOAGLAND**, JUDGE).

Subsequent members serve four-year terms and are eligible for reappointment. Individuals employed by drug manufacturers, or their trade associations, are prohibited.

¹ [Or. Const. art. III, sect. 4](#); [ORS 171.562 and 171.565 \(2023\)](#).

² [ORS 244.050 \(2023\)](#).

³ [ORS 646A.693 \(2023\)](#); [ORS 182.100 \(2023\)](#) for affirmative action policy; [ORS 236.115 \(2023\)](#) for diversity criteria.

The board selects its chair and vice chair. The board is required to meet once every six weeks at, so long as there are prescription drugs under review.

Duties⁴

The board is established in the Department of Consumer Affairs and Business Services (DCBS) to protect residents, state and local governments, commercial health plans, health care providers, pharmacies, and other stakeholders from the high costs of prescription drugs. The board must also:

- identify at least nine drugs and one insulin product annually as specified that it determines will pose cost challenges for patients or health care systems;
- report to the legislature and the Health Care Cost Growth Target program annually as specified, on price trends and drugs that were reviewed; and,
- study the national market for generic drugs as specified and report to the legislature annually.

⁴ [ORS 646A.693 to 646A.697 \(2023\)](#)



Prescription Drug Affordability Board

Agency: **Consumer & Business Services, Department of**

Policy Area: **Health**

Authorization: **ORS 646A.693**

Board Admin: **Ralph Magrish**

Min Members: **5** Max Members: **8**

Address:

Term Length: **4** Term Limit: **None**

Senate Confirmation Required?: **Yes**

Ralph.M.MAGRISH@dcbs.oregon.gov

Current Appointments

Bailey, Shelley Term(s): **6/10/2022 - 12/31/2026**

Position Number: **1**

Dr Burns, Amy M Term(s): **1/1/2025 - 12/31/2028**

Position Number: **2** **9/28/2022 - 12/31/2024**

Mr Kennedy, Daniel Term(s): **6/5/2024 - 12/31/2025**

Position Number: **3**

Hartung, Daniel Term(s): **6/10/2022 - 12/31/2025**

Position Number: **4**

Hoagland, Lauri Term(s): **10/1/2024 - 12/31/2026**

Position Number: **5**

Mr Judge, Robert M Term(s): **6/10/2022 - 12/31/2026**

Position Number: **6**

Laman, Christopher Term(s): **2/16/2024 - 12/31/2025**

Position Number: **7**

Murray, John Term(s): **1/1/2025 - 12/31/2028**

Position Number: **8** **9/28/2022 - 12/31/2024**

Vacant Positions